Precigen receives FDA Breakthrough Therapy Designation for PRGN-2012

Precigen announced that the U.S. FDA has granted Breakthrough Therapy Designation for the first-in-class investigational PRGN-2012 AdenoVerse immunotherapy for the treatment of recurrent respiratory papillomatosis.